Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7505473 | 0.84 | ALDH1A1 (0.70) | SMN1; SMN2ALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL4000768 | 0.83 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL7955066 | 0.83 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL6270349 | 0.82 | KMT2A (0.54) | SMN1; SMN2ALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL23120213 | 0.81 | SMN1; SMN2 (0.66) | SMN1; SMN2ALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL11438039 | 0.81 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL29663590 | 0.81 | SMN1; SMN2 (0.66) | SMN1; SMN2ALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL10792203 | 0.81 | ALDH1A1 (0.50) | ALDH1A1KMT2AMEN1L3MBTL1KDM4E | |
| SCHEMBL17507541 | 0.81 | ATM (0.55) | SMN1; SMN2KMT2AMEN1GAAMAPT | |
| SCHEMBL28984810 | 0.81 | KMT2A (0.54) | SMN1; SMN2ALDH1A1KMT2AMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117304033-A | Caffeic acid derivative and preparation method thereof, pharmaceutical composition and application | 中国医学科学院药物研究所 | 2023-12-29 | — | — | CN | disclosed |
| EP-3705479-A1 | NEW AMIDE DERIVATIVES OF CINCHONA ALKALOIDS, METHOD FOR THE PREPARATION THEREOF AND USE THEREOF IN ASYMMETRIC PHASE TRANSFER REACTIONS | Instytut Chemii Organicznej Polskiej Akademii Nauk (PL) | 2020-09-09 | — | — | EP | disclosed |
| EP-2185562-B1 | PYRROLOPYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-02 | — | — | EP | disclosed |
| US-8318731-B2 | Pyrrolopyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-27 | — | — | US | disclosed |
| US-20100204197-A1 | PYRROLOPYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-12 | — | — | US | disclosed |
| US-7101891-B2 | Compounds and pharmaceutical compositions for inhibiting MRP1 | ELI LILLY AND COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| US-20040116460-A1 | Compounds and pharmaceutical compositions for inhibiting mrp1 | COHEN JEFFREY DANIEL (US) | 2004-06-17 | — | — | US | disclosed |
| EP-1392701-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002081480-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204197-A1 | PYRROLOPYRIMIDINES | PLK4, PLK2, PLK3 | SMN1; SMN2 4113/4885ALDH1A1 2934/4885KMT2A 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.